Profit-Taking Hits Moderna Stock After mRNA-1010 Wins Unanimous FDA Panel Backing
Decision due Aug 5, 2026. Potential 2026–27 launch.
/ 83 items
#XY News-Driven Stocks↓
Butterfly Network Soars as Midjourney Enters Medical Imaging with Revolutionary Full-Body Ultrasound Scanner
AI-powered 60-second scans could transform preventive healthcare.
Edwards Lifesciences Gets Big Boost as CMS Expands TAVR Coverage to Asymptomatic Patients
TAVR is Edwards’ main business. New CMS rules could boost sales and help it take market share from Medtronic and Boston Scientific.
CMS Plans Permanent Medicare Drug Price Negotiations Starting 2029 – What It Means for Big Pharma
Medicare plans drug price cuts from 2029, hitting pharma stocks, but long-term impact may be limited by legal and market protections.
Biggest Nursing Home Company Accused of Cutting Corners on Patient Care
Hunterbrook report accuses Ensign Group of understaffing, gaming metrics, and patient neglect.
Liquidia Gets Bullish Signal from Hikma vs Amarin Ruling
Raymond James reiterates Strong Buy rating and $68 target on Liquidia after the Supreme Court’s positive Hikma v. Amarin decision.